Previous 10 | Next 10 |
2024-01-21 01:55:00 ET Summary Lee’s Pharm acquired China rights to a heart failure therapy from Windtree Therapeutics. AstraZeneca signed an investment cooperation agreement with the Taizhou National Medical High-tech Development Zone to build a new production line in its ...
WARRINGTON, PA / ACCESSWIRE / January 18, 2024 / Greater China holds a significant, if not the world's largest, acute heart failure patient population. It may be a market where drug treatment innovation can help patients and that's what Windtree Therapeutics Inc. (NASDAQ:WINT) is hoping to acc...
Windtree to receive potential future milestones up to $138MM plus up to low double digit royalties and full coverage for all development, manufacturing, regulatory and commercialization costs for products in the licensed territory Lee’s plans to initiate and fund Phase 3 for ista...
The new preclinical data further supports istaroxime clinical data from three Phase 2 studies Arrythmias can be a serious complication of current rescue therapies for treatment of patients with acute heart failure WARRINGTON, Pa., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Windtree The...
WARRINGTON, PA / ACCESSWIRE / December 19, 2023 / Windtree Therapeutics, Inc. (NASDAQ:WINT) has recently enrolled the first subject in its phase 2 SEISMiC Extension Study to evaluate istaroxime in the treatment of early cardiogenic shock. The phase 2 trial builds upon the positive data from the ...
SEISMiC Extension Study results are anticipated in mid-2024 and expected to provide dose optimization for Phase 3 The Company is also progressing a parallel SCAI Stage C Phase 2 study with istaroxime in cardiogenic shock targeting data in a similar timeframe WARRINGTON, Pa., Dec...
2023-12-01 08:25:56 ET Losers: Smart for Life ( SMFL ) -38% announces exercise of warrants for $1.5 Million gross proceeds . Ampio Pharmaceuticals ( AMPE ) -34% . Incannex Healthcare ( IXHL ) -34% . Vivos Therapeutics ( VVOS ) -14% . ...
WARRINGTON, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the European Patent O...
NEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November 15-16, 2023. The presentation schedule is...
Windtree Therapeutics Inc. (WINT) is expected to report for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Windtree Therapeutics Inc. Company Name:
WINT Stock Symbol:
OTCMKTS Market:
WARRINGTON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it...
A look at the top 10 most actives in the United States Chicken Soup for the Soul Entertainment Inc. (CSSE) rose 43.1% to $0.218 on volume of 39,190,339 shares Amesite Inc. (AMST) rose 100.0% to $4.0001 on volume of 36,290,765 shares Tesla Inc. (TSLA) rose 10.7% to $160.21 on volume of 32,...
2024-04-22 11:06:19 ET Windtree Therapeutics Inc (NASDAQ: WINT) is down nearly 20% on Monday even though there hasn’t been any specific news that may have caused that decline. Here’s what may be weighing on Windtree Therapeutics stock Investors may be continuing to...